Lakefront Biotherapeutics (LKFT) Total Liabilities (2014 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly Total Liabilities of $139.4 million for Q1 2026, down 89.6% year-over-year from $1.3 billion in Q1 2025, and down 29.83% quarter-over-quarter from $198.6 million in Q4 2025.
Lakefront Biotherapeutics (LKFT) Total Liabilities (2014 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Total Liabilities for 13 consecutive years, with $139.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities fell 89.6% year-over-year to $139.4 million; the TTM figure through Mar 2026 stood at $139.4 million (down 89.6% YoY), while the FY2025 annual figure was $198.6 million, down 84.99% from the prior year.
- Total Liabilities eased to $139.4 million in Q1 2026 per LKFT's latest filing, from $198.6 million in the prior quarter.
- Across five years, Total Liabilities topped out at $2.8 billion in Q1 2022 and bottomed at $139.4 million in Q1 2026.
- Historically, Total Liabilities has averaged $1.5 billion across 5 years, with a median of $1.4 billion in 2024.
- Annual changes were most pronounced in 2025 — Total Liabilities decreased 13.44% — and 2026, when it tumbled 89.6%.
- Lakefront Biotherapeutics' Total Liabilities stood at $2.3 billion in 2022, then declined by 25.41% to $1.7 billion in 2023, then retreated by 21.23% to $1.3 billion in 2024, then tumbled by 84.99% to $198.6 million in 2025, then declined by 29.83% to $139.4 million in 2026.
- Business Quant data shows LKFT's Total Liabilities at $139.4 million in Q1 2026, $198.6 million in Q4 2025, and $1.2 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Lakefront Biotherapeutics | 1.81 Bn | -1.68 Bn | 1.97 Mn | 139.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 139.39 Mn |
| Dec 31, 2025 | 198.64 Mn |
| Sep 30, 2025 | 1.24 Bn |
| Jun 30, 2025 | 1.33 Bn |
| Mar 31, 2025 | 1.34 Bn |
| Dec 31, 2024 | 1.32 Bn |
| Sep 30, 2024 | 1.44 Bn |
| Mar 31, 2024 | 1.59 Bn |
| Dec 31, 2023 | 1.68 Bn |
| Sep 30, 2023 | 1.99 Bn |
| Mar 31, 2023 | 2.22 Bn |
| Dec 31, 2022 | 2.25 Bn |
| Mar 31, 2022 | 2.75 Bn |
| Dec 31, 2021 | 2.92 Bn |
| Jun 30, 2021 | 3.33 Bn |
| Dec 31, 2020 | 3.63 Bn |
| Jun 30, 2020 | 3.39 Bn |
| Mar 31, 2020 | 3.48 Bn |
| Dec 31, 2019 | 3.53 Bn |
| Sep 30, 2019 | 3.69 Bn |